Answers are grounded in this paper and cite their sources.
Background: Skin flap necrosis remains one of the most challenging complications in reconstructive and plastic surgery, primarily driven by ischemia-reperfusion injury and microvascular insufficiency. Botulinum Toxin Type A (BTX-A) has emerged as a promising pharmacological agent to enhance flap survival through mechanisms including vasodilation, local sympathetic denervation, reduction of metabolic demand, and anti-inflammatory properties. However, conflicting preclinical data regarding optimal dosing, timing, and administration routes necessitate a comprehensive synthesis. Objective: This systematic review and meta-analysis aim to critically evaluate the efficacy of BTX-A pretreatment in enhancing random-pattern skin flap survival in animal models, assessing flap necrosis percentage, perfusion parameters, and tissue viability markers (e.g., VEGF, CD31).
No takes yet. Share an insight, caveat, or question.
Aydin Ghaffari (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: